Filariasis News and Research

RSS
Filariasis (Philariasis) is a parasitic and infectious tropical disease, that is caused by thread-like filarial nematode worms in the superfamily Filarioidea, also known as "filariae". There are 9 known filarial nematodes which use humans as the definitive host.

Further Reading

Brandeis professor investigates wallpaper-like liner technology for tackling malaria

Brandeis professor investigates wallpaper-like liner technology for tackling malaria

Major effort to tackle neglected tropical diseases

Major effort to tackle neglected tropical diseases

Abbott, DNDi partner to research on new treatments for NTDs

Abbott, DNDi partner to research on new treatments for NTDs

U.K. government to increase NTD spending fivefold between 2011 and 2015

U.K. government to increase NTD spending fivefold between 2011 and 2015

International public health spending ignores neglected tropical diseases, some experts argue

International public health spending ignores neglected tropical diseases, some experts argue

Disease mapping could help control and eliminate loiasis, other NTDs, study says

Disease mapping could help control and eliminate loiasis, other NTDs, study says

Ivermectin cream demonstrates activity against head lice eggs

Ivermectin cream demonstrates activity against head lice eggs

MSU professor focuses on new formulation for old drug to treat parasitic diseases

MSU professor focuses on new formulation for old drug to treat parasitic diseases

FDA accepts Topaz's ivermectin NDA for treatment for head lice infestations

FDA accepts Topaz's ivermectin NDA for treatment for head lice infestations

Sanofi, DNDi announce three-year research collaboration for neglected tropical diseases

Sanofi, DNDi announce three-year research collaboration for neglected tropical diseases

NIAID team completes analysis of most proteins produced by elephantiasis parasite worm

NIAID team completes analysis of most proteins produced by elephantiasis parasite worm

Anacor Pharma, MMV enter agreement to develop AN3661 for malaria treatment

Anacor Pharma, MMV enter agreement to develop AN3661 for malaria treatment

ITMNs can reduce Japanese Encephalitis transmission to humans

ITMNs can reduce Japanese Encephalitis transmission to humans

Anacor and iOWH establish research agreement to identify new drugs for shigellosis

Anacor and iOWH establish research agreement to identify new drugs for shigellosis

New study on mosquito genome sequences to identify 'transposable elements'

New study on mosquito genome sequences to identify 'transposable elements'

Bill Gates' annual letter calls for focus on eradicating polio, governments to sustain foreign aid

Bill Gates' annual letter calls for focus on eradicating polio, governments to sustain foreign aid

Anacor, UCSF and NYBC collaborate to discover drug therapies for river blindness

Anacor, UCSF and NYBC collaborate to discover drug therapies for river blindness

Eisai signs statement of intent with WHO to supply medicine for treatment of lymphatic filariasis

Eisai signs statement of intent with WHO to supply medicine for treatment of lymphatic filariasis

Report documents increase in R&D projects on developing world diseases

Report documents increase in R&D projects on developing world diseases

Discovery of anti-parasitic drug mechanism could lead to new treatments for filarial diseases

Discovery of anti-parasitic drug mechanism could lead to new treatments for filarial diseases

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.